QR-Code

Docetaxel and Ramucirumab as Subsequent Treatment After First-Line Immunotherapy-Based Treatment for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Study and Literature Review

<b>Background</b>: A combination of docetaxel and ramucirumab represents a standard of care in second-line treatment for patients with advanced NSCLC. Evidence of the regimen’s efficacy is based on the results of the REVEL trial conducted in the pre-immunotherapy (immune checkpoint inhibitors–ICIs)...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Sotiris Loizidis, Paris Vogazianos, Zoe Kordatou, Georgios Fotopoulos, George Orphanos, Flora Kyriakou, Haris Charalambous
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI AG 2025-11-01
Schriftenreihe:Current Oncology
Schlagworte:
immunotherapy
antiangiogenic agents
non-small-cell lung cancer
VEGF
docetaxel
ramucirumab
Online-Zugang:https://www.mdpi.com/1718-7729/32/11/612
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge